Clinical trial of 2-bromo-alpha-ergocryptine (NSC-169774) in human prostatic cancer.

Clinical trial of 2-bromo-alpha-ergocryptine (NSC-169774) in human prostatic cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Clinical trial of 2-bromo-alpha-ergocryptine (NSC-169774) in human prostatic cancer. Abstract Text:

A Coune,P Smith,

An EORTC type I clinical trial of 2-bromo-alpha ergocryptine was performed in patients with prostatic carcinoma in clinical stages III and IV. Evaluating rules of response to the therapy were based on objective criteria. The maximum period of followup was 16 weeks. No objective remissions were observed in 24 patients, and in 13 of these patients, evidence of progression of the disease was apparent during the first 8 weeks of drug administration.

Clinical trial of 2-bromo-alpha-ergocryptine (NSC-169774) in human prostatic cancer. Publishing Authors By Initials

A Coune,P Smith,

For similar pathological conditions, signs and symptoms: signs and symptoms: signs and symptoms, digestive: vomiting research abstracts see: pathological conditions, signs and symptoms: signs and symptoms: signs and symptoms, digestive: vomiting research

PUBMED ID PMID:

MEDLINE DATE: 1975 Jan-Feb

Clinical trial of 2-bromo-alpha-ergocryptine (NSC-169774) in human prostatic cancer. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Cancer chemotherapy reports. Part 1

VOLUME: 59

Page Numbers: 209-13

Journal Abbreviation:

ISSN: 0069-0112

DAY: 20

MONTH: 02

YEAR: 2008

Clinical trial of 2-bromo-alpha-ergocryptine (NSC-169774) in human prostatic cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7607105

Clinical trial of 2-bromo-alpha-ergocryptine (NSC-169774) in human prostatic cancer. Keywords Mesh Terms:

KEYWORDS: Vomiting

MESH TERMS: chemically induced

Chemical & Substance for Abstract: Clinical trial of 2-bromo-alpha-ergocryptine (NSC-169774) in human prostatic cancer. Information

Substance Name: Prolactin

Registry Number: 9002-62-4

Grant and Affiliation Information for Clinical trial of 2-bromo-alpha-ergocryptine (NSC-169774) in human prostatic cancer.

AFFILIATION:

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cancer Chemother Rep

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Clinical trial of 2-bromo-alpha-ergocryptine NSC-169774 in human prostatic cancer Related Publications

• 10 do's and don'ts about tax homes.
• A gravitational lens.
• An animal evaluation of a paste of chitosan glutamate and hydroxyapatite as a synthetic bone graft material.
• An electrostrictive drive for fine pitch control in double-crystal monochromators.
• Animal model of human disease: inherited erythrocyte glutathione deficiency.
• Bacterial pathogens of the respiratory tract of the newborn infant.
• Brain uptake of nonsteroidal anti-inflammatory drugs: ibuprofen, flurbiprofen, and indomethacin.
• Calculating Society's Willingness to Pay for a QALY : Key Questions for Discussion.
• Characterizing the structures and folding of free proteins using 2-D gas-phase separations: observation of multiple unfolded conformers.
• Coccidioidomycosis.
• Demoralization, anhedonia and grief in patients with severe physical illness.
• Developmental outcomes after early or delayed insertion of tympanostomy tubes.
• Effects of hormone-induced superovulation on latent infectious bovine rhinotracheitis virus in cattle.
• Euphemistic codes and tell-tale hearts: humane assistance in end-of-life cases.
• Evaluation of beta-endorphin and naloxone on bovine uterine motility.
• Gastrointestinal disease in adolescents.
• Increased amyloid- levels in APPSWE transgenic mice treated chronically with a physiological high-fat high-cholesterol diet.
• Joys of teaching nursing.
• Occupational health in India.
• Odontoblast morphology and dental repair.
• Practical management of tuberculosis.
• Preventing and treating: Heart disease in women.
• Synthesis of 4,4-difluoroglycosides using ring-closing metathesis.
• The Herpesvirus capsid surface protein, VP26, and the majority of the tegument proteins are dispensable for capsid transport toward the nucleus.
• The effects of rhBMP-2 on human osteosarcoma cells and human gingival fibroblasts in vitro.
• The effects of xylazine hydrochloride on intrauterine pressure in the cow.
• The reliability of willingness to pay for changes in health status.
• The role of primary care in infertility management.
• What is happening in the real world in lipid therapy and is it appropriate? The need for a paradigm shift.
• X-ray Imaging and Microspectroscopy of Plants and Fungi.